Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is currently the leading prophylactic vaccine for COVID-19 based on forecast sales as it is expected to be the first globally available vaccine for COVID-19. BNT-162b2 is expected to generate a whopping $30 billion in sales from 2020 to 2026, with peak sales of $13.9 billion in 2021, says GlobalData.
The main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics.
Commenting about the Pfizer-BioNTech vaccine, Keshalini Sabaratnam, Pharma Analyst at GlobalData, said, “Despite being the first available vaccine, BNT-162b2’s sales are forecasted to decline by a staggering 76 percent in 2022 to $3.4 billion due to competition expected from future COVID-19 vaccine approvals. Nonetheless, COVID-19 vaccines will continue to be in demand beyond 2022 if COVID-19 turns out to be a seasonal or long-term concern.”
Also read: Pfizer gets USFDA nod for blood cancer drug
The main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics, whereas Moderna’s vaccine candidate mRNA-1273, which can be stored and shipped at -20°C, could be a more attractive alternative.
“Pfizer-BioNTech’s BNT-162b2 vaccine breakthrough marks a significant turning point in the global battle against COVID-19. It raises hopes that life could return to normal by next winter; however, post-marketing surveillance will be critical to detect any rare serious adverse events, as there has not yet been an mRNA vaccine that has gone through the full regulatory pathway for approval,” Sabaratnam added.